A PYMNTS Company

US: Allergan must face antitrust class action over Alzheimer’s drug

By  |  September 15, 2016

A proposed class action lawsuit brought by a health plan and a drug wholesaler accusing Allergan PLC of suppressing competition for its Alzheimer’s drug Namenda can move forward, a federal judge ruled on Tuesday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    US District Judge Colleen McMahon in Manhattan denied Allergan’s motion to dismiss the lawsuit, which makes similar allegations to a 2014 lawsuit brought by New York Attorney General Eric Schneiderman.

    That lawsuit stopped the company from forcing patients to switch to a new version of the drug before generic versions of the old version hit the market.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.